difelikefalin: Clinical Trials

8 trials of difelikefalin, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

4 completed, 4 terminated. 8 Phase 3, 1 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 38Completed 4, Terminated 4
Phase 21Terminated 1

Follow difelikefalin: new trials by email Literature Review of difelikefalin trials Research Report on difelikefalin

Trials (filtered) newest first · largest first

All 8 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Study to Evaluate the Efficacy and Safety of Oral Difelikefalin for Moderate to Severe Pruritus in Subjects With Notalgia Paresthetica
difelikefalin 2.0 mg tablets, difelikefalin 1.0 mg tablets, difelikefalin 0.25 mg tablets - Pruritus, Notalgia Paresthetica
Phase 2 / Phase 3TerminatedCara Therapeutics, Inc.2142023-08-012024-06-21
Phase 3 Study of Difelikefalin in Haemodialysis Chinese Adult Subjects With Moderate-to-Severe Pruritus
Difelikefalin Injection, Placebo Injection - Uremic Pruritus
Phase 3CompletedVifor Fresenius Medical Care Renal Pharma2602023-05-182025-09-12
CR845-310302: A Study to Evaluate the Safety and Efficacy of Difelikefalin in Advanced Chronic Kidney Disease Patients With Moderate-to-Severe Pruritus
Difelikefalin 1 mg Oral Tablet, Placebo Oral Tablet - Chronic Kidney Diseases, Pruritus
Phase 3TerminatedCara Therapeutics, Inc.1052022-08-262024-05-07
Study to Evaluate the Efficacy and Safety of Oral Difelikefalin as Adjunct Therapy to a Topical Corticosteroid for Moderate to Severe Pruritus in Subjects With Atopic Dermatitis
difelikefalin 0.25 mg, difelikefalin 0.5 mg, TCS Cream - Pruritus, Atopic Dermatitis
Phase 3TerminatedCara Therapeutics, Inc.2872022-08-162024-02-22
A Study to Evaluate the Safety and Efficacy of Difelikefalin in Advanced Chronic Kidney Disease Patients With Moderate-to-Severe Pruritus
Difelikefalin 1 mg Oral Tablet, Placebo Oral Tablet - Chronic Kidney Diseases, Pruritus
Phase 3TerminatedCara Therapeutics, Inc.2862022-05-172024-05-07
CR845-CLIN3105: A Study to Evaluate the Safety and Effectiveness of CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus
CR845 0.5 mcg/kg - Uremic Pruritus
Phase 3CompletedCara Therapeutics, Inc.2222019-05-062021-10-15
CR845-CLIN3103: A Global Study to Evaluate the Safety and Efficacy of CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus
CR845 0.5 mcg/kg, Placebo - Uremic Pruritus
Phase 3CompletedCara Therapeutics, Inc.4732018-07-172022-04-26
A Study to Evaluate the Safety and Efficacy of CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus (KALM-1)
CR845 0.5 mcg/kg, Placebo - Uremic Pruritus
Phase 3CompletedCara Therapeutics, Inc.3782018-02-202022-04-26

Conditions studied

Pruritus (7)  ·  Kidney Failure, Chronic (5)  ·  Renal Insufficiency, Chronic (5)  ·  Dermatitis, Atopic (1)  ·  Eczema (1)

Sponsors

Cara Therapeutics, Inc. (7)  ·  Vifor Fresenius Medical Care Renal Pharma (1)

Countries

United States (7)  ·  Poland (4)  ·  Germany (3)  ·  Hungary (3)  ·  Australia (2)  ·  Canada (2)  ·  Czechia (2)  ·  South Korea (2)  ·  Spain (2)  ·  Argentina (1)  ·  Brazil (1)  ·  Bulgaria (1)  ·  China (1)  ·  Italy (1)  ·  Mexico (1)

Top investigators

Milica Enoiu, PhD (1)

Results publications

PMID 36039153, PMID 37968132, PMID 39037824, PMID 33283264, PMID 36016762, PMID 31702883, PMID 36185706, PMID 37927032, PMID 38196014, PMID 41686509